West-Central Africa EMERGENTS International Center of Excellence in Malaria Research (ICEMR)
Project Number1U19AI181594-01
Contact PI/Project LeaderDINGLASAN, RHOEL DAVID RAMOS Other PIs
Awardee OrganizationUNIVERSITY OF FLORIDA
Description
Abstract Text
OVERALL RESEARCH STRATEGY
ABSTRACT/SUMMARY
Despite significant progress to reduce global malaria incidence and related deaths over the past 20
years, this positive trend is now in a state of decline. Data from 2021 indicated that the global milestones
set out in WHO's global technical strategy for malaria 2016-30 (GTS) were not met, with both case and mortality
targets being off track by 48%. Increasing insecticide and drug resistance, limited sensitivity of field diagnostic
tools and declining investments are urgent contributory factors to the decline in coverage and effectiveness of
routine control interventions. To date, the true contribution of non-falciparum malaria (NFM) – often presenting
as asymptomatic infection – to the global disease burden remains underappreciated. While P. vivax (Pv) has
risen in research priority over the past 10 years, research into the fundamental epidemiology and transmission
dynamics of of P. ovale (Po wallikeri [Pow] and Po curtisi [Poc]) and P. malariae (Pm) has been largely neglected.
Quantifying the asymptomatic malaria reservoir in human populations has been a priority topic for current ICEMR
programs, yet deeper insight into this issue is elusive. A concurrent biological threat to malaria control is the
invasion and spread of Anopheles stephensi Liston (AS) into the Horn of Africa and movement westward into
Central and West Africa, presenting a serious concern to control efforts across the continent. Sympatric Pv and
AS will change the dynamics of malaria control, as not only is AS a competent vector for Pf/Pv where both are
endemic (e.g., South Asia), it has also demonstrated preference for similar breeding habitats as the urban
dengue vector Aedes aegypti, risking a return of malaria into highly dense, urbanized cities and towns throughout
SSA. How the expansion of AS to areas with different climates and ecologies will affect malaria transmission
remains to be seen. Tackling existing obstacles to achieving global malaria elimination goals thus remains only
partly, if not poorly addressed. The West-Central Africa Enhancing Malaria Epidemiology Research through
Genomics & Translational Systems biology (Émergents [fr.]) ICEMR program leverages successful, well-
established collaborations, unique advanced research and training infrastructures, and an extensive Sub-
Saharan Africa (SSA) research network to address emerging and challenging issues in malaria transmission in
the region. Émergents ICEMR is built on a proven research platform and consortium of World Bank, Wellcome
Trust-, African Academy of Sciences-, and NIH/CDC-funded centers of excellence in Cameroon and Nigeria.
This Émergents ICEMR program will focus research in Nigeria and Cameroon, proposing three interwoven
programmatic packages (PP): PP1. Genomic Epidemiological Mapping (GEM) of non-falciparum malaria
(NFM; Pv, Po, and P. malariae [Pm]) to quantify the parasite reservoir, measure transmissibility to
mosquitoes and evaluate the insecticide resistance status of mosquitoes with NFM parasite infections;
PP2. Bionomics, Ecology, & Control of An. stephensi (BECA) against the background of endemic primary
and secondary anopheline vectors; PP3. Advancing Clinical and Entomological Surveillance (ACES)
through emergent diagnostic and translational systems biology platforms to address emerging issues
viz. asymptomatic malaria and non-falciparum malaria transmission in the context of Malaria Elimination
and Eradication (MEE). To date, there has been no ICEMR program in the Central-West Africa nexus, which
appears to be the leading edge of two new invasive species to Sub-Saharan Africa, namely Pv and An. stephensi
in two bordering countries with high malaria burden (Nigeria and Cameroon). Émergents ICEMR directly fills
this unmet public health vacuum. Considering the established network of collaborations westward to Ghana and
southwards to the Democratic Republic of Congo, the Émergents ICEMR can serve as an effective springboard
to support and advance malaria research and training in an expansive region representing diverse malaria
burden, eco-epidemiological landscapes, and emerging risk to the invasive species.
Public Health Relevance Statement
OVERALL RESEARCH STRATEGY
PROJECT NARRATIVE
Increasing insecticide and drug resistance, limited sensitivity of field diagnostic tools and declining investments
are urgent contributory factors to the decline in coverage and effectiveness of routine control interventions for
malaria control and elimination. Moreover, the true contribution of non-falciparum malaria (NFM) – often
presenting as asymptomatic infection – to the global disease burden remains underappreciated. The West-
Central Africa Enhancing Malaria Epidemiology Research through Genomics & Translational Systems biology
(Émergents [fr.]) ICEMR program is built on a proven research platform and consortium of World Bank, Wellcome
Trust, African Academy of Sciences-, and NIH/CDC-funded centers of excellence in Cameroon and Nigeria, and
will leverage this expertise to focus on (a) Genomic Epidemiological Mapping (GEM) of non-falciparum malaria
(NFM) to quantify the parasite reservoir, measure transmissibility to mosquitoes and evaluate the insecticide
resistance status of mosquitoes with NFM parasite infections; (b) Bionomics, Ecology, & Control of Anopheles
stephensi (BECA) against the background of endemic primary and secondary anopheline vectors; and (c)
Advancing Clinical and Entomological Surveillance (ACES) through emergent diagnostic and translational
systems biology platforms to address emerging issues viz. asymptomatic malaria and non-falciparum malaria
transmission.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AcademyAddressAedesAffectAfricaAfrica South of the SaharaAfricanAnopheles GenusAreaAsiaBiologicalBreedingCOVID-19 pandemicCameroonCentral AfricaCessation of lifeCitiesClimateClinicalCollaborationsCountryCulicidaeDataDemocratic Republic of the CongoDengueDiagnosticDiseaseDjiboutiDrug resistanceEcologyEffectivenessEpidemiologyFundingGenomicsGhanaGoalsHabitatsHornsHumanIncidenceIndividualInfectionInfrastructureInsecticide ResistanceInterventionInvadedInvestmentsKnowledgeLiverMalariaMapsMeasuresMovementNigeriaNorth AmericaParasitesParasitic infectionPlasmodium falciparumPlasmodium ovalePlasmodium vivaxPopulationPublic HealthReportingResearchResearch InfrastructureResearch PriorityResourcesRiskScienceSustainable DevelopmentSystems BiologyTrainingTraining and InfrastructureTrustUnited States National Institutes of HealthUrbanizationVacuumWorld Bankburden of illnessdensitydiagnostic toolepidemiology studygenomic epidemiologyinsightinternational centermalaria transmissionmanmortalityneglectpreferenceprogramssyndemictransmission processtrendvectorvector mosquito
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
969663814
UEI
NNFQH1JAPEP3
Project Start Date
22-April-2024
Project End Date
31-March-2029
Budget Start Date
22-April-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$747,123
Direct Costs
$551,121
Indirect Costs
$196,002
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$747,123
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U19AI181594-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U19AI181594-01
Patents
No Patents information available for 1U19AI181594-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U19AI181594-01
Clinical Studies
No Clinical Studies information available for 1U19AI181594-01
News and More
Related News Releases
No news release information available for 1U19AI181594-01
History
No Historical information available for 1U19AI181594-01
Similar Projects
No Similar Projects information available for 1U19AI181594-01